Catalina Capital Group LLC Sells 1,093 Shares of Stryker Corporation (NYSE:SYK)

Catalina Capital Group LLC trimmed its position in shares of Stryker Corporation (NYSE:SYK - Free Report) by 55.3% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 885 shares of the medical technology company's stock after selling 1,093 shares during the period. Catalina Capital Group LLC's holdings in Stryker were worth $329,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Capital & Planning LLC boosted its stake in shares of Stryker by 3.6% in the fourth quarter. Capital & Planning LLC now owns 841 shares of the medical technology company's stock worth $304,000 after acquiring an additional 29 shares during the period. Brighton Jones LLC lifted its holdings in Stryker by 15.4% in the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company's stock worth $1,643,000 after purchasing an additional 609 shares in the last quarter. Van ECK Associates Corp boosted its stake in Stryker by 1.3% in the 4th quarter. Van ECK Associates Corp now owns 13,035 shares of the medical technology company's stock worth $4,693,000 after purchasing an additional 173 shares during the period. Empower Advisory Group LLC grew its holdings in Stryker by 52.3% during the 4th quarter. Empower Advisory Group LLC now owns 1,991 shares of the medical technology company's stock valued at $717,000 after buying an additional 684 shares in the last quarter. Finally, Venturi Wealth Management LLC raised its position in shares of Stryker by 2.4% during the fourth quarter. Venturi Wealth Management LLC now owns 1,789 shares of the medical technology company's stock valued at $644,000 after buying an additional 42 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Truist Financial raised their target price on shares of Stryker from $390.00 to $400.00 and gave the company a "hold" rating in a research note on Monday, May 5th. BTIG Research set a $403.00 price objective on shares of Stryker and gave the company a "buy" rating in a report on Monday, April 14th. JMP Securities reaffirmed a "market perform" rating on shares of Stryker in a report on Monday, May 5th. The Goldman Sachs Group set a $422.00 target price on Stryker in a research report on Tuesday, March 4th. Finally, Roth Mkm raised their price target on Stryker from $405.00 to $456.00 and gave the company a "buy" rating in a report on Friday, May 2nd. Four equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $427.30.

Stryker Trading Down 0.0%

NYSE:SYK traded down $0.15 during midday trading on Thursday, hitting $373.22. 854,682 shares of the company traded hands, compared to its average volume of 1,333,573. The firm has a market capitalization of $142.45 billion, a P/E ratio of 50.43, a P/E/G ratio of 2.82 and a beta of 0.91. The firm's fifty day moving average is $373.92 and its 200-day moving average is $375.52. Stryker Corporation has a 12-month low of $314.93 and a 12-month high of $406.19. The company has a current ratio of 1.64, a quick ratio of 1.00 and a debt-to-equity ratio of 0.69.

Stryker (NYSE:SYK - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, beating the consensus estimate of $2.73 by $0.11. The business had revenue of $5.87 billion for the quarter, compared to the consensus estimate of $5.68 billion. Stryker had a net margin of 12.31% and a return on equity of 23.74%. The business's revenue for the quarter was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.50 earnings per share. On average, sell-side analysts predict that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.90%. The ex-dividend date of this dividend is Monday, June 30th. Stryker's payout ratio is currently 45.41%.

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 200,000 shares of the firm's stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the completion of the sale, the director now directly owns 3,417,326 shares of the company's stock, valued at approximately $1,288,195,208.96. This trade represents a 5.53% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 5.90% of the company's stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.